hrs4r
 I want to donate

JOAQUIM BOSCH BARRERA

Firma
JOAQUIM BOSCH-BARRERA
Position
Cap de Grup - R4
Group leader - R4

Projectes

Codi oficial: Pfizer 2019 Joaquim Bosch Start date:05/07/2019 Data fi: 31/12/2024 Investigador/a principal: JOAQUIM BOSCH BARRERA, JAVIER ABEL MENÉNDEZ MENÉNDEZ Organisme finançador: PFIZER, S.L.U.
Codi oficial: 101057509 Start date:01/11/2022 Data fi: 31/10/2027 Investigador/a principal: JOAN BRUNET VIDAL, RAMON BRUGADA TERRADELLAS, RAMON BRUGADA TERRADELLAS Organisme finançador: EUROPEAN COMISSION
Codi oficial: 2021 SGR 01507 Start date:01/01/2022 Data fi: 30/06/2025 Investigador/a principal: BEGOÑA MARTIN CASTILLO Organisme finançador: AGENCIA DE GESTIO D'AJUTS UNIV. I RECER.

Publicacions

Candal-Pedreira C, Ruano-Ravina A, Calvo de Juan V, Cobo M, Trigo JM, Rodríguez-Abreu D, Estival A, Carcereny E, Cucurull M, López Castro R, Medina A, García Campelo R, Cordeiro González P, Sánchez-Gastaldo A, Bosch-Barrera J, Massutí B, Dómine M, Camps C, Ortega AL, Sánchez-Hernández A, Guirado Risueño M, Del Barco Morillo E, Garrido Fernández A, Provencio M

Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients.

ARCHIVOS DE BRONCONEUMOLOGIA, 2024, 60, 88-94 dx.doi.org/10.1016/j.arbres.2023.12.005
Karachaliou N, Codony-Servat J, Teixidó C, Pilotto S, Drozdowskyj A, Codony-Servat C, Giménez-Capitán A, Molina-Vila MA, Bertrán-Alamillo J, Gervais R, Massuti B, Morán T, Majem M, Felip E, Carcereny E, García-Campelo R, Viteri S, González-Cao M, Morales-Espinosa D, Verlicchi A, Crisetti E, Chaib I, Santarpia M, Luis Ramírez J, Bosch-Barrera J, Felipe Cardona A, de Marinis F, López-Vivanco G, Miguel Sánchez J, Vergnenegre A, Sánchez Hernández JJ, Sperduti I, Bria E, Rosell R

Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.

SCIENTIFIC REPORTS, 2023, 13, 3620-3620 dx.doi.org/10.1038/s41598-023-30374-9
Teixidor E, Sais E, Vásquez CA, Carbajal W, Hernández A, Sánchez G, Izquierdo A, Verdura S, Menéndez JA, Bosch-Barrera J

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Oncotarget, 2023, 14, 668-668 dx.doi.org/10.18632/oncotarget.28471
Janik A, Torrente M, Costabello L, Calvo V, Walsh B, Camps C, Mohamed SK, Ortega AL, Novácek V, Massutí B, Minervini P, Campelo MRG, Del Barco E, Bosch-Barrera J, Menasalvas E, Timilsina M, Provencio M

Machine Learning-Assisted Recurrence Prediction for Patients With Early-Stage Non-Small-Cell Lung Cancer.

Jco Clinical Cancer Informatics, 2023, 7 dx.doi.org/10.1200/CCI.22.00062
Provencio M, Nadal E, González-Larriba JL, Martínez-Martí A, Bernabé R, Bosch-Barrera J, Casal-Rubio J, Calvo V, Insa A, Ponce S, Reguart N, de Castro J, Mosquera J, Cobo M, Aguilar A, López Vivanco G, Camps C, López-Castro R, Morán T, Barneto I, Rodríguez-Abreu D, Serna-Blasco R, Benítez R, Aguado de la Rosa C, Palmero R, Hernando-Trancho F, Martín-López J, Cruz-Bermúdez A, Massuti B, Romero A

Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.

NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389, 504-513 dx.doi.org/10.1056/NEJMoa2215530
Aparicio I, Iranzo P, Reyes R, Bote H, Saigi M, Bringas M, Bosch-Barrera J, Corral J, Aparisi F, Ruffinelli JC, Jiménez B, Lage Y, López-Castro R, Majem M, Vázquez S, Artal Á, Rodríguez-Pérez Á, Lázaro-Quintela M, Torres JMS, Reguart N, Cucurull M, Gil-Bazo I, Camps C, Nadal E, Del Barrio A, Garrido P, Dómine M, Álvarez R, Muñoz AJ, Calles A

Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer.

THROMBOSIS RESEARCH, 2023, 232, 133-137 dx.doi.org/10.1016/j.thromres.2023.11.007
Candal-Pedreira C, Ruano-Ravina A, Calvo de Juan V, Cobo M, Trigo JM, Carcereny E, Cucurull M, López Castro R, Solís García E, Sánchez-Gastaldo A, Massutí B, Rodríguez-Abreu D, Estival A, Guirado Risueño M, Pamiés Ramón M, García Campelo R, Alonso-Jáudenes G, Camps C, Del Barco Morillo E, González Ojea C, Dómine M, Sanchez-Hernandez A, Bosch-Barrera J, Sala González MÁ, Provencio M

Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study.

ERJ Open Research, 2023, 9 dx.doi.org/10.1183/23120541.00468-2023
Provencio M, Carcereny E, López Castro R, Calvo V, Rodríguez Abreu D, Cobo M, Ortega AL, Bernabé R, Guirado M, Massutí B, Del Barco-Morillo E, Bosch-Barrera J, Camps C, Carroll R, Rault C, Chaib C, Penrod J, Vo L, Ralphs E, Daumont MJ

Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study.

Translational Lung Cancer Research, 2023, 12, 2113-2128 dx.doi.org/10.21037/tlcr-23-176
Provencio M, Estival A, Franco F, López-Vivanco G, Saigí M, Arasanz H, Diz P, Carcereny E, García J, Aguado C, Mosquera J, Iruarrizaga E, Majem M, Bosch-Barrera J, Mielgo-Rubio X, Guirado M, Juan-Vidal Ó, Blasco A, Lucía Gozálvez C, Del Barrio A, De Portugal T, López-Martín A, Serrano G, Campos B, Rubio J, Catot S, Esteban B, Martí-Ciriquian JL, Del Barco E, Calvo V, Spanish Lung Cancer Group (SLGC/GECP)

Immunogenicity of COVID-19 vaccines in lung cancer patients.

LUNG CANCER, 2023, 184, 107323-107323 dx.doi.org/10.1016/j.lungcan.2023.107323
Bosch-Barrera J, Roqué A, Teixidor E, Carmona-Garcia MC, Arbusà A, Brunet J, Martin-Castillo B, Cuyàs E, Verdura S, Menendez JA

Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin

Pharmaceuticals, 2022, 15 dx.doi.org/10.3390/ph15010019

Propietat intel·lectual

Joaquim Bosch Barrera

MEANS FOR PREVENTING AND TREATING BRAIN METASTASIS

Número de publicació: EP20170382891 Data de publicació: 2019-06-26

Formulari de contacte

About IDIBGI!

menu